ALLUVI: A DEEP DIVE INTO THE DRUG'S POTENTIAL

Alluvi, formerly LY3414901, represents a exciting advancement in obesity management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receiver agonist exhibits remarkable impact in early medical data, with substantial weight loss observed in